Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood. (OBEGEN)
Primary Purpose
Obesity, Child
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
sequencing of a panel of 14 genes in leptin melanocortin pathway
Sponsored by
About this trial
This is an interventional diagnostic trial for Obesity, Child
Eligibility Criteria
Inclusion Criteria: severe obesity with BMI > 3SDS Exclusion Criteria: genetic obesity (Prader Willi syndrome, Bardet Biedl syndrome, X fragile syndrome, Alstrom syndrome) BMI < 3 SDS age < 6 months monogenic non syndromic obesity, with mutation in genes of leptin melanocortin pathway previously diagnosed cushing syndrome
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
severe obese children
Arm Description
children with severe obesity with BMI > 3sds
Outcomes
Primary Outcome Measures
frequency of mutations of genes from leptin melanocortin pathway
Evaluating of the frequency of mutations of 14 genes from leptin melanocortin pathway (LEP, LEPR, POMC, PCSK1, MC3R, MC4R, MRAP2, ADCY3, SIM1, SH2B1, NTRK2, BDNF, KSR2) in a group of french children with severe obesity.
Secondary Outcome Measures
Clinical characteristics of children with severe obesity followed in CHRU of Nancy
Description of the clinical characteristics : height in cm BMI
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description of the clinical characteristics :thyroid function (TSH T3 T4)
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description of the clinical characteristics : IGF1 levels
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description of the clinical characteristics :BMI in kg/m²
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description of the clinical characteristics : weight in kg
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description of the clinical characteristics : bone age (X ray of the left hand)
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description of the clinical characteristics : metabolic profile
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description of the clinical characteristics : leptin level
Penetrance of mutations from leptin melanocortin pathway
Evaluation of the penetrance of mutation from leptin melanocortin pathway, that is to say the percentage of obesity in mutation carrier
effect of age, sex, country of birth on mutations' penetrance.
Evaluation of the effect of age, sex, country of birth on mutations' penetrance.
Clinical characteristics of children with severe obesity followed in CHRU of Nancy
Description of Clinical characteristics of children with severe obesity followed in CHRU of Nancy : weight in kg Description of the clinical characteristics :
Clinical characteristics of children with severe obesity followed in CHRU of Nancy
Description of the clinical characteristics :BMI in kg/m²
Full Information
NCT ID
NCT05938335
First Posted
June 12, 2023
Last Updated
July 3, 2023
Sponsor
Central Hospital, Nancy, France
1. Study Identification
Unique Protocol Identification Number
NCT05938335
Brief Title
Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood.
Acronym
OBEGEN
Official Title
Results of Sequencing of a Large Panel of Genes From Leptin Melanocortin Pathway in Children Suffering From Severe Obesity
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2023 (Anticipated)
Primary Completion Date
October 1, 2024 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Central Hospital, Nancy, France
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
About 380 million children and adolescents suffer from overweight and obesity at the global level. Obesity results from the interplay between biological (sex, age, fetal programming, gut microbiota, epigenetics, and genetics) and environmental factors (e.g., unhealthy diet, physical inactivity, stress). Mutations in genes from leptin melanocortin pathway are involved in "non syndromic monogenic obesity", characterized by severe early onset obesity, hyperphagia and endocrine deficiencies. Exact frequencies of mutation in these genes are not precisely evaluated in french children with severe obesity. Moreover new treatment, such seltmelanotide are avalaible in case of certain mutation, leading to a significative weight loss in treated patients.
Detailed Description
Obesity is a global health concern that affected more than 650 million adult people and more than 380 million children and adolescents worldwide, with no signs of slowing down despite major investments in health policy. Obestiy is a multifactorial disease, but 40 to 75% of body mass index (BMI) variation is explained by genetic factors.
Mutations in genes from leptin melanocortin pathway lead to "non syndromic monogenic obesity", characterized by severe early onset obesity, hyperphagia and endocrine deficiencies. This pathway plays a central role in regulating mammalian food intake, energy expenditure and body weight regulation. Somes genes are well characterized such LEP gene, LEPR gene, or MC4R but others have been recently described as ADCY3, SIM1, SH2B1, NTRK2, BDNF, KSR2.
The frequency of these mutations are not precisely estimated in a group of french children with severe obesity.
Moreover, a precocious identification of these mutations, could afford, in certain case the possibility of a efficient treatment with setmelanotide, leading to a significant weight loss in treated patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Child
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
severe obese children
Arm Type
Experimental
Arm Description
children with severe obesity with BMI > 3sds
Intervention Type
Genetic
Intervention Name(s)
sequencing of a panel of 14 genes in leptin melanocortin pathway
Intervention Description
sequencing (NGS) of a panel of 14 genes in leptin melanocortin pathway in french children with severe obesity
Primary Outcome Measure Information:
Title
frequency of mutations of genes from leptin melanocortin pathway
Description
Evaluating of the frequency of mutations of 14 genes from leptin melanocortin pathway (LEP, LEPR, POMC, PCSK1, MC3R, MC4R, MRAP2, ADCY3, SIM1, SH2B1, NTRK2, BDNF, KSR2) in a group of french children with severe obesity.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Clinical characteristics of children with severe obesity followed in CHRU of Nancy
Description
Description of the clinical characteristics : height in cm BMI
Time Frame
1 year
Title
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description
Description of the clinical characteristics :thyroid function (TSH T3 T4)
Time Frame
1 year
Title
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description
Description of the clinical characteristics : IGF1 levels
Time Frame
1 year
Title
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description
Description of the clinical characteristics :BMI in kg/m²
Time Frame
1 year
Title
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description
Description of the clinical characteristics : weight in kg
Time Frame
1 year
Title
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description
Description of the clinical characteristics : bone age (X ray of the left hand)
Time Frame
1 year
Title
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description
Description of the clinical characteristics : metabolic profile
Time Frame
1 year
Title
Clinical characteristics of children with mutations of leptin melanocortin pathway
Description
Description of the clinical characteristics : leptin level
Time Frame
1 year
Title
Penetrance of mutations from leptin melanocortin pathway
Description
Evaluation of the penetrance of mutation from leptin melanocortin pathway, that is to say the percentage of obesity in mutation carrier
Time Frame
1 year
Title
effect of age, sex, country of birth on mutations' penetrance.
Description
Evaluation of the effect of age, sex, country of birth on mutations' penetrance.
Time Frame
1 year
Title
Clinical characteristics of children with severe obesity followed in CHRU of Nancy
Description
Description of Clinical characteristics of children with severe obesity followed in CHRU of Nancy : weight in kg Description of the clinical characteristics :
Time Frame
1 year
Title
Clinical characteristics of children with severe obesity followed in CHRU of Nancy
Description
Description of the clinical characteristics :BMI in kg/m²
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
severe obesity with BMI > 3SDS
Exclusion Criteria:
genetic obesity (Prader Willi syndrome, Bardet Biedl syndrome, X fragile syndrome, Alstrom syndrome)
BMI < 3 SDS
age < 6 months
monogenic non syndromic obesity, with mutation in genes of leptin melanocortin pathway previously diagnosed
cushing syndrome
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Emeline RENARD
Phone
+33383154500
Email
e.renard@chru-nancy.fr
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood.
We'll reach out to this number within 24 hrs